1. Home
  2. IMNN vs GRNQ Comparison

IMNN vs GRNQ Comparison

Compare IMNN & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • GRNQ
  • Stock Information
  • Founded
  • IMNN 1982
  • GRNQ 2013
  • Country
  • IMNN United States
  • GRNQ Malaysia
  • Employees
  • IMNN N/A
  • GRNQ N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • GRNQ EDP Services
  • Sector
  • IMNN Health Care
  • GRNQ Technology
  • Exchange
  • IMNN Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • IMNN 12.9M
  • GRNQ 12.1M
  • IPO Year
  • IMNN 1985
  • GRNQ 2018
  • Fundamental
  • Price
  • IMNN $4.39
  • GRNQ $1.42
  • Analyst Decision
  • IMNN Buy
  • GRNQ
  • Analyst Count
  • IMNN 2
  • GRNQ 0
  • Target Price
  • IMNN $182.61
  • GRNQ N/A
  • AVG Volume (30 Days)
  • IMNN 79.1K
  • GRNQ 819.2K
  • Earning Date
  • IMNN 11-05-2025
  • GRNQ 11-13-2025
  • Dividend Yield
  • IMNN N/A
  • GRNQ N/A
  • EPS Growth
  • IMNN N/A
  • GRNQ N/A
  • EPS
  • IMNN N/A
  • GRNQ N/A
  • Revenue
  • IMNN N/A
  • GRNQ $3,256,679.00
  • Revenue This Year
  • IMNN N/A
  • GRNQ N/A
  • Revenue Next Year
  • IMNN N/A
  • GRNQ N/A
  • P/E Ratio
  • IMNN N/A
  • GRNQ N/A
  • Revenue Growth
  • IMNN N/A
  • GRNQ N/A
  • 52 Week Low
  • IMNN $4.33
  • GRNQ $0.80
  • 52 Week High
  • IMNN $41.22
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 30.98
  • GRNQ 49.28
  • Support Level
  • IMNN $4.44
  • GRNQ $1.25
  • Resistance Level
  • IMNN $4.90
  • GRNQ $1.52
  • Average True Range (ATR)
  • IMNN 0.32
  • GRNQ 0.10
  • MACD
  • IMNN -0.04
  • GRNQ 0.00
  • Stochastic Oscillator
  • IMNN 2.09
  • GRNQ 62.96

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: